HeyJaredWhat's it Worth? A Journal Club Podcast
Get into the weeds with us as we take deep dives into clinical trials and build the essential skills of evidence critique!
- Indexed episodes, last 90 days
- 6
- Latest publication
- Aug 11, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 14, 2026
Latest episodes
S4E10 - Watchman Vs. DOACs for Prevention of Stroke & Systemic Embolism (opens the original)
Read excerpt
Stroke prevention in atrial fibrillation is always a balancing act: reduce clot risk without causing unacceptable bleeding. For years, oral anticoagulants have been the cornerstone of that decision. But what happens when a device enters the conversation? In this episode, host Dr. Diana Langworthy is joined by Dr. Jen Osborn , cardiology clinical pharmacy specialist at UMMC East Bank Hospital and residency program director for the PGY2 Thrombosis and Hemostasis Management Residency. Together, the
S4E9.5 - What's it Worth? For Everyone. Can Lavender Oil Help Anxiety? What to Know About Silexan (opens the original)
Read excerpt
In this What's It Worth? For Everyone episode, we're asking: Can lavender oil help with anxiety? If you've ever felt anxious before a big test, job interview, medical appointment, or major life event, you're not alone. But when is anxiety a normal response to stress — and when is it something more, like generalized anxiety disorder? In this episode, we talk about the difference between short-term situational anxiety and ongoing anxiety symptoms that may need support from a healthcare professiona
S4E9 - Anxiety Treatment Rankings: What a Network Meta-Analysis Can and Can't Tell Us (opens the original)
Read excerpt
Welcome back to What's it Worth? In this episode, we tackle treatment options for a common mental health concern - anxiety. Your host, Dr. Diana Langworthy, is joined by Dr. Lucas Kosobuski , an inpatient pharmacist at St. Luke's in Duluth with prior experience providing ambulatory care services in an inpatient substance use treatment program. Together, they decode a 2025 systematic review and network meta-analysis comparing medications for anxiety disorders, including Silexan , a proprietary or
S4E8 - Is it Possible to Decouple Bleeding from Clotting? Insights from the AZALEA-TIMI 71 Trial (Factor XI Series Part 2 of 2) (opens the original)
Read excerpt
In Part 2 of our back-to-back series on the novel frontier of Factor XI inhibition, host Dr. Diana Langworthy and student co-hosts Caleb Nelson-Lange and Tim Haas dive into the AZALEA-TIMI 71 trial. Following our Part 1 discussion on the early termination of the OCEANIC-AF trial (asundexian), we turn our attention to abelacimab —a high-affinity, fully human monoclonal antibody that targets Factor XI. Unlike the small-molecule asundexian, abelacimab offers a unique pharmacokinetic profile with a
S4E8.5 - What's it Worth? For Everyone. Are We Waiting Too Long for New Treatments? (opens the original)
Read excerpt
In this What's It Worth? For Everyone episode, we're asking: Are we waiting too long for new treatments? If you've ever heard about a promising new medication, peptide, or breakthrough therapy and wondered, "If it works so well, why isn't everyone using it yet?" —you're not alone. It can feel frustrating to hear about exciting discoveries while waiting years before they become part of routine healthcare. In this episode, we take you behind the scenes of the scientific process to explore what hap
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.